Try our beta test site

Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group Identifier:
First received: December 15, 2011
Last updated: July 7, 2016
Last verified: July 2016

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies biomarkers in tumor samples from younger patients with neuroblastoma.

Condition Intervention
Genetic: fluorescence in situ hybridization
Genetic: gene expression analysis
Genetic: microarray analysis
Genetic: mutation analysis
Genetic: protein analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Other: microscopy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Proposed Studies on the Role of Growth Factor Receptor Trafficking in Neuroblastoma Pathogenesis

Resource links provided by NLM:

Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • Expression of UBE4B, hrs, and members of the ubiquitination protein complex
  • Expression levels and cellular localization of the UBE4B, hrs, and growth factor receptors
  • 1p36 deletion status and its association with UBE4B

Biospecimen Retention:   Samples With DNA
Tumor samples

Estimated Enrollment: 5
Study Start Date: December 2011
Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Detailed Description:


  • To determine the expression of UBE4B, hrs, and members of the ubiquitination protein complex in previously banked primary neuroblastoma tumor samples from the Children's Oncology Group.
  • To determine the correlation of expression levels and cellular localization of the UBE4B and hrs proteins with growth factor-receptor tumor cell-surface expression.
  • To determine the 1p36 deletion status by fluorescence in situ hybridization (FISH) analysis and their association with expression levels of UBE4B and hrs in previously banked primary neuroblastoma tumor samples from the Children's Oncology Group.

OUTLINE: Banked tumor tissue samples are analyzed for expression of UBE4B, hrs, members of the ubiquitination protein complex, growth factor receptors, and 1p36 deletion status by immunohistochemistry (IHC), fluorescent microscopy, and fluorescence in situ hybridization (FISH).


Ages Eligible for Study:   up to 120 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients With Neuroblastoma


  • Tumor tissue microarrays from the Children's Oncology Group neuroblastoma tumor bank


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01493830

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Peter Zage, MD, PhD Texas Children's Cancer Center
  More Information

Responsible Party: Children's Oncology Group Identifier: NCT01493830     History of Changes
Other Study ID Numbers: ANBL12B4  COG-ANBL12B4  NCI-2012-00091  ANBL12B4 
Study First Received: December 15, 2011
Last Updated: July 7, 2016

Keywords provided by Children's Oncology Group:

Additional relevant MeSH terms:
Neuroectodermal Tumors, Primitive, Peripheral
Neuroectodermal Tumors, Primitive
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue processed this record on February 24, 2017